197 related articles for article (PubMed ID: 31015455)
1. K27-linked ubiquitination of BRAF by ITCH engages cytokine response to maintain MEK-ERK signaling.
Yin Q; Han T; Fang B; Zhang G; Zhang C; Roberts ER; Izumi V; Zheng M; Jiang S; Yin X; Kim M; Cai J; Haura EB; Koomen JM; Smalley KSM; Wan L
Nat Commun; 2019 Apr; 10(1):1870. PubMed ID: 31015455
[TBL] [Abstract][Full Text] [Related]
2. The APC/C E3 Ligase Complex Activator FZR1 Restricts BRAF Oncogenic Function.
Wan L; Chen M; Cao J; Dai X; Yin Q; Zhang J; Song SJ; Lu Y; Liu J; Inuzuka H; Katon JM; Berry K; Fung J; Ng C; Liu P; Song MS; Xue L; Bronson RT; Kirschner MW; Cui R; Pandolfi PP; Wei W
Cancer Discov; 2017 Apr; 7(4):424-441. PubMed ID: 28174173
[TBL] [Abstract][Full Text] [Related]
3. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
[TBL] [Abstract][Full Text] [Related]
4. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.
Hoeflich KP; Herter S; Tien J; Wong L; Berry L; Chan J; O'Brien C; Modrusan Z; Seshagiri S; Lackner M; Stern H; Choo E; Murray L; Friedman LS; Belvin M
Cancer Res; 2009 Apr; 69(7):3042-51. PubMed ID: 19276360
[TBL] [Abstract][Full Text] [Related]
5. Synergistic cytotoxicity of radiation and oncolytic Lister strain vaccinia in (V600D/E)BRAF mutant melanoma depends on JNK and TNF-α signaling.
Kyula JN; Khan AA; Mansfield D; Karapanagiotou EM; McLaughlin M; Roulstone V; Zaidi S; Pencavel T; Touchefeu Y; Seth R; Chen NG; Yu YA; Zhang Q; Melcher AA; Vile RG; Pandha HS; Ajaz M; Szalay AA; Harrington KJ
Oncogene; 2014 Mar; 33(13):1700-12. PubMed ID: 23624923
[TBL] [Abstract][Full Text] [Related]
6. Ring finger protein 149 is an E3 ubiquitin ligase active on wild-type v-Raf murine sarcoma viral oncogene homolog B1 (BRAF).
Hong SW; Jin DH; Shin JS; Moon JH; Na YS; Jung KA; Kim SM; Kim JC; Kim KP; Hong YS; Lee JL; Choi EK; Lee JS; Kim TW
J Biol Chem; 2012 Jul; 287(28):24017-25. PubMed ID: 22628551
[TBL] [Abstract][Full Text] [Related]
7. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
[TBL] [Abstract][Full Text] [Related]
8. The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma.
Ramsdale R; Jorissen RN; Li FZ; Al-Obaidi S; Ward T; Sheppard KE; Bukczynska PE; Young RJ; Boyle SE; Shackleton M; Bollag G; Long GV; Tulchinsky E; Rizos H; Pearson RB; McArthur GA; Dhillon AS; Ferrao PT
Sci Signal; 2015 Aug; 8(390):ra82. PubMed ID: 26286024
[TBL] [Abstract][Full Text] [Related]
9. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
[TBL] [Abstract][Full Text] [Related]
10. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
[TBL] [Abstract][Full Text] [Related]
11. HDAC8 Regulates a Stress Response Pathway in Melanoma to Mediate Escape from BRAF Inhibitor Therapy.
Emmons MF; Faião-Flores F; Sharma R; Thapa R; Messina JL; Becker JC; Schadendorf D; Seto E; Sondak VK; Koomen JM; Chen YA; Lau EK; Wan L; Licht JD; Smalley KSM
Cancer Res; 2019 Jun; 79(11):2947-2961. PubMed ID: 30987999
[TBL] [Abstract][Full Text] [Related]
12. Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition.
Kim HS; Jung M; Kang HN; Kim H; Park CW; Kim SM; Shin SJ; Kim SH; Kim SG; Kim EK; Yun MR; Zheng Z; Chung KY; Greenbowe J; Ali SM; Kim TM; Cho BC
Oncogene; 2017 Jun; 36(23):3334-3345. PubMed ID: 28092667
[TBL] [Abstract][Full Text] [Related]
13. Regulation of BRAF protein stability by a negative feedback loop involving the MEK-ERK pathway but not the FBXW7 tumour suppressor.
Hernandez MA; Patel B; Hey F; Giblett S; Davis H; Pritchard C
Cell Signal; 2016 Jun; 28(6):561-71. PubMed ID: 26898828
[TBL] [Abstract][Full Text] [Related]
14. Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers.
Kotani H; Adachi Y; Kitai H; Tomida S; Bando H; Faber AC; Yoshino T; Voon DC; Yano S; Ebi H
Oncogene; 2018 Mar; 37(13):1775-1787. PubMed ID: 29348459
[TBL] [Abstract][Full Text] [Related]
15. An oncogenic mutant of RHEB, RHEB Y35N, exhibits an altered interaction with BRAF resulting in cancer transformation.
Heard JJ; Phung I; Potes MI; Tamanoi F
BMC Cancer; 2018 Jan; 18(1):69. PubMed ID: 29320991
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
Nakamura A; Arita T; Tsuchiya S; Donelan J; Chouitar J; Carideo E; Galvin K; Okaniwa M; Ishikawa T; Yoshida S
Cancer Res; 2013 Dec; 73(23):7043-55. PubMed ID: 24121489
[TBL] [Abstract][Full Text] [Related]
17. Mitogen-activated protein kinase dependency in BRAF/RAS wild-type melanoma: A rationale for combination inhibitors.
Ming Z; Lim SY; Kefford RF; Rizos H
Pigment Cell Melanoma Res; 2020 Mar; 33(2):345-357. PubMed ID: 31518489
[TBL] [Abstract][Full Text] [Related]
18. ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma.
Ojha R; Leli NM; Onorati A; Piao S; Verginadis II; Tameire F; Rebecca VW; Chude CI; Murugan S; Fennelly C; Noguera-Ortega E; Chu CT; Liu S; Xu X; Krepler C; Xiao M; Xu W; Wei Z; Frederick DT; Boland G; Mitchell TC; Karakousis GC; Schuchter LM; Flaherty KT; Zhang G; Herlyn M; Koumenis C; Amaravadi RK
Cancer Discov; 2019 Mar; 9(3):396-415. PubMed ID: 30563872
[TBL] [Abstract][Full Text] [Related]
19. Phosphorylation of the E3 ubiquitin protein ligase ITCH diminishes binding to its cognate E2 ubiquitin ligase.
Perez JM; Chen Y; Xiao TS; Abbott DW
J Biol Chem; 2018 Jan; 293(3):1100-1105. PubMed ID: 29212706
[TBL] [Abstract][Full Text] [Related]
20. KIT Suppresses BRAF
Neiswender JV; Kortum RL; Bourque C; Kasheta M; Zon LI; Morrison DK; Ceol CJ
Cancer Res; 2017 Nov; 77(21):5820-5830. PubMed ID: 28947418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
